Bridge Therapy Between Induction, ASCT May Slow Neuroblastoma
Bridging therapy before ASCT improved event-free survival for patients with stable metastatic disease at the end of induction.
Hematopoietic Stem Cell Transplantation
ASCT Extends PFS in Newly Diagnosed Multiple Myeloma
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
Delays in Initiation of Revaccination in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Initiation of revaccination appears to be delayed for a significant portion of pediatric patients following allo-HSCT.
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Transplant Approach Produces “Promising” Long-Term Outcomes in Kids With Blood Cancers
The approach resulted in low rates of graft failure, viral infections, and relapse.
Costs of Care and Complication Rates Among Patients With Hematologic Malignancies Undergoing Allo-HCT
Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.
Outcomes of Pediatric Patients With Steroid-Refractory Acute Graft Vs Host Disease
Steroid-refractory acute GVHD is associated with high mortality rates in pediatric patients, despite second-line treatment.
Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
- Loading...
Loading...
Next post in Tandem Meetings 2022
Loading... 
Loading...